Verition Fund Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Verition Fund Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.55M	Buy	+2,000	New	+$1.53M	0.01%	1144
2025 Q3	–	Sell	-5,000	Closed	-$2.63M	–	3963
2025 Q2	$2.63M	Buy	+5,000	New	+$2.79M	0.01%	1728
2025 Q1	–	Sell	-3,400	Closed	-$2.42M	–	3651
2024 Q4	$2.42M	Sell	3,400 -300	-8%	-$252K	0.01%	1430
2024 Q3	$3.89M	Hold	3,700	–	–	0.02%	1017
2024 Q2	$3.89M	Hold	3,700	–	–	0.02%	869
2024 Q1	$3.56M	Buy	3,700 +900	+32%	+$856K	0.02%	890
2023 Q4	$2.46M	Buy	2,800 +1,700	+155%	+$1.4M	0.02%	743
2023 Q3	$905K	Buy	+1,100	New	+$865K	0.01%	1136
2022 Q4	–	Sell	-500	Closed	-$344K	–	2621
2022 Q3	$344K	Buy	+500	New	+$315K	﹤0.01%	2128
2022 Q2	–	Sell	-2,800	Closed	-$1.96M	–	2934
2022 Q1	$1.96M	Buy	2,800 +400	+17%	+$253K	0.02%	985
2021 Q4	$1.52M	Buy	+2,400	New	+$1.48M	0.01%	1043

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Verition Fund Management's REGN Position: Q1 2026 in Review

Verition Fund Management reduced its Regeneron Pharmaceuticals (REGN) stake by 84% in Q1 2026, selling an estimated $6.13M and leaving 1,478 shares worth $1.14M. The position accounts for 0.01% of the portfolio, ranked #1254.

Verition Fund Management first reported a position in REGN in Q2 2013 and has held it in 42 quarters since. The position peaked at $18.7M in Q4 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Verition Fund Management held 1,478 shares of Regeneron Pharmaceuticals worth $1.14M as of Q1 2026.
Verition Fund Management sold 8,013 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $6.13M.
Regeneron Pharmaceuticals made up 0.01% of Verition Fund Management's portfolio in Q1 2026, its #1254 holding.
Verition Fund Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
Verition Fund Management's Regeneron Pharmaceuticals position peaked at $18.7M in Q4 2024.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.